Novo Nordisk Navigates U.S. Weight-Loss Drug Market Challenges

Novo Nordisk, known for its success with obesity drugs, confronts a major hurdle in expanding within the U.S. weight-loss drug market. The company's market position has waned due to competition from Eli Lilly and rising sales of cheaper alternatives.

In response, the Novo Nordisk Foundation, a key investor and non-profit organization, has assumed control of the board, emphasizing a renewed focus on the pivotal U.S. market to drive sales for Wegovy. Former CEO Lars Rebien Sorensen criticized the board's slow adaptation to a dynamic, consumer-oriented obesity market.

Novo is enhancing its consumer strategies, including leveraging online health platforms and exploring insurance coverage options, as it prepares for the launch of a weight-loss pill. Analysts highlight the need for more consumer-centric approaches to meet Wall Street forecasts.